Assessing Digital Health Technologies, Including DTx, Across the Four Biggest European Markets

Since our last whitepaper on digital therapeutics (DTx) in Europe, much has changed on the digital health and digital therapeutics landscape. Many European countries have established new assessment frameworks and evidence requirements for the evaluation of digital health products, including DTx. New medical device regulations define and categorize DTx, and the brand-new European pharmaceutical strategy prioritizes digital health infrastructure and its objectives.

In this whitepaper, we consider current assessment frameworks across the four biggest European countries: Germany, the United Kingdom, France, and Italy, and we look at current DTx reimbursement policies.

Highlights include:

Relevant legislative developments at the European level
Assessment of DTx across four major European countries (Germany, England, France, and Italy
Learnings from the first HTA submissions and DiGA’s arrival in care pathways
Comparison of assessment criteria for digital health products accross countries

We are excited to share our latest thinking with you.

Please fill out the form to download the whitepaper.

"*" indicates required fields

X/Twitter

This field is for validation purposes and should be left unchanged.

First Name*

Last Name*

Company Name*

Job Title*

Work Email*

Select the solutions you’re interested in (if any)

By submitting your information, you agree to receive communications from OPEN Health. We will use your information in accordance with our Privacy Notice.

At OPEN Health, we connect visionary minds, pioneering science, and advanced technology to drive real impact.

By uniting people, science, and technology, we activate new opportunities for biopharma innovation. Our expertise across medical affairs and market access unlocks faster, smarter routes to market. We are committed to improving patient outcomes worldwide.

Talk to us